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Abstract
Osteoarthritis (OA) is a debilitating joint disorder with a complex pathogeny 
wherein diverse factors interact, causing a process of deterioration of the articular 
cartilage and the subchondral bone. It can be primary or secondary but has com-
mon clinical, radiological, and pathological manifestations. Unfortunately, there 
are no curative or preventive options available for this disease. The knee is the most 
common site to develop OA among all synovial joints. Both environmental and 
genetic factors play an essential role in the initiation of the disease. Identifying the 
genes underlying the genetic background could give new insights into the patho-
physiology of knee osteoarthritis (KOA) and could potentially lead to new drug 
targets. Several genes involving developmental processes or maintenance of carti-
lage and bone are found to be associated with KOA susceptibility and progression. 
Understanding the gene functions has improved the knowledge towards the disease 
pathogenesis. So, it will be of interest to investigate the role of gene-gene interaction 
in the disease.
Keywords: KL grade, knee osteoarthritis, single nucleotide polymorphism, VAS, 
WOMAC
1. Introduction
Osteoarthritis (OA) is the most common degenerative arthritis caused by the 
breakdown of articular cartilage [1]. The prevalence of OA is high and expected 
to increase in the coming years [2]. Results of some epidemiologic studies indicate 
that the incidence of symptomatic OA is about 8–9% in China [3]. OA is a multi-
factorial joint disorder in which growing age, genetic factors; hormonal as well as 
mechanical factors are significant contributors to its onset and progression. The 
molecular mechanism underlying the cartilage degeneration is poorly understood 
[4]. American College of Rheumatology defines Osteoarthritis as a heterogonous 
group of condition that leads to joint symptoms and signs which are associated 
with defective integrity of articular cartilage, in addition to related changes in the 
underlying bone at joint margin [5]. OA is primarily a non-inflammatory disorder 
of movable joint characterized by an imbalance between the synthesis and degrada-
tion of articular cartilage, leading to the classic pathological change of wearing 
away and destruction of cartilage [6]. OA affects nearly 21 million people in the 
United States, accounting for 25% of the visits to primary care physicians and half 
of all having NSAID (Non- Steroid Anti Inflammatory drugs) prescriptions. It is 
estimated that about 80% of the population was having radiographic evidence 
of Osteoarthritis by the age of 65 years, although only about 60% of these were 
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symptomatic [7]. Epidemiological profile of Osteoarthritis in India is not clear, 
but it is estimated that more than 30-40% of the Indian population suffers from 
Osteoarthritis over the age of 50 years (www.wrongdiagnosis.com).




Primary OA is a chronic degenerative condition of mobile joints due to an 
unknown cause. This may result due to aging because few people do not show any 
clinical or functional signs of the diseases in the late 90s. The proteoglycan and 
water content of the cartilage reduce with the advancement of age, hence the tough-
ness of cartilage and increasing the susceptibility of collagen fibers to degenerate 
[8]. Mild inflammation around the joint capsule may occur in OA as compared to 
rheumatoid arthritis. This inflammation is in response to the small particles of the 
debris produced by this cartilage breakage and then attempted clearance by the 
scavengers cells located in joint lining [8]. New bone outgrowths called ‘spurs’ or 
osteophytes may form on the margins of the joint, possibly in an attempt to improve 
the congruence of the articular cartilage surfaces. Some of these bone changes, 
along with low-grade inflammation, may cause pain and mobility.
3. Secondary osteoarthritis
This type of OA is caused by other factors or disease, but the resulting patho-
logical changes are the same as for primary OA.
Leading causes of secondary Osteoarthritis:
• Accidental injury to joints [9].
• Inflammatory diseases [7] (such as Perthes disease, Lyme disease) and all 
chronic form of arthritis (e.g. gout, pseudogout and rheumatoid arthritis). In 
gout, uric acid crystals cause cartilage degradation at a faster pace [10].
• Healed infection of the joints.
• Sports injuries [11]
According to Creamer et al. [12], Knee Osteoarthritis (OA) is a significant cause 
of disability, particularly in older people. The factors determining disability remain 
unclear. A study was conducted to assess the impact of clinical and psychosocial 
variables on function in knee Osteoarthritis and to develop models to account for 
observed variance in self-reported disability. It was conducted that function in 
symptomatic knee Osteoarthritis is determined more by pain and obesity than 
by structural changes as seen on plain X-ray. Hunter and Felson [13] said that 
Osteoarthritis had been known believed to be a disease of articular cartilage since 
ages, but the current concept is entirely different. Hunter and Felson explained that 
OA is a structural and functional impairment of synovial joints resulting in a range 
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of disease. OA entails the whole joint including the subchondral bone, menisci, 
ligaments, periarticular muscle, capsule and synovium.
Osteoarthritis (OA) is a chronic degenerative disorder of multifactorial etiology 
characterized by loss of articular cartilage, hypertrophy of bone at the margins, 
subchondral sclerosis and range of biochemical and morphological alterations of 
the synovial membrane and joint capsule. It may be either Primary Osteoarthritis 
or Secondary Osteoarthritis. Primary OA is mostly related to aging. It can present 
as localized, generalized or as erosive Osteoarthritis. Another disease or condition 
causes secondary OA [14].
Osteoarthritis (OA) is a disease of the musculoskeletal system that primarily 
involves the joints of the knee, hip, spine, hand and foot. OA is estimated to affect 
40% of people >70 years of age [15], making it more prevalent than any other form 
of arthritis [16]. The Framingham Knee Osteoarthritis study suggests that knee 
osteoarthritis increases in prevalence throughout the elderly, more so in women 
than in men [17]. Females are found to have more severe OA, more number of joints 
are involved, and have more symptoms and increased hand and knee OA [18]. 
Osteoarthritis (OA) is the most common cause of musculoskeletal disability related 
to aging and is characterized by late-onset degeneration of articular cartilage [19]. 
OA is one of the leading causes of disability and dysfunction in the elderly popula-
tion [20]; it has been estimated that the total cost for arthritis, including OA, is over 
2% of the United States gross domestic product [21].
Prevalence of OA: Osteoarthritis (OA) is the second most common rheuma-
tological problem and is the most frequent joint disease with a prevalence of 80% 
in the population having radiographic evidence. About 60% of radiographically 
evidenced subjects are symptomatic [22]. In India, more than 41.1% of the popula-
tion suffers from Osteoarthritis beyond the age of 50 years [23]. This is the most 
common cause of locomotor disability in the elderly [24]. More than 20 million 
people are affected with OA in the United States, including 10% of adults of age 
50 years. It has been estimated that 2% of women and 1.4% of men develop radio-
graphic OA per year, but approx half of these individual show symptoms [19].
Etiology of OA: OA is a multifactorial disease with both genetic and environ-
mental determinants, and all cases are probably affected by both, with a continuous 
distribution between the extremes of genetic or predominantly environmental 
causes [15]. The pathophysiology of OA is complex and do not comprehend with 
its clinical feature. The disease is rare before the age of 40 years but frequency 
increases with age as large no. of individual with ≥70 years demonstrate radio-
graphic evidence of OA in some joints. All cases are probably affected by both 
genetics and environment, with a continuous distribution between the extremes of 
predominantly genetic or predominantly environmental causes [15].
Role of genes in OA: Role of genetics is emerging as an important etiological 
factor in recent times. More than 65 genes are associated with knee osteoarthritis 
(KOA) in different populations, and Indian population candidate genes like CALM-1 
[25], VDR gene polymorphism [26], GDF-5 [22], SMAD-3, BMP-5, CCL2, COL2A1 
[27] and COL2A1, CRTL1 [28] are associated with KOA. In recent years many studies 
have been conducted on KOA to investigate its association with SNPs. Genome-Wide 
Association Stu is performed on a large scale to identify the role of different loci in 
the development of the disease depending on the number of variants used. To date, 
more than ten loci (LSP1P3, GDF5, CHST11, FTO, GNL3, ASTN2, SENP6, PTHLH, 
TP63, CDC5L and CHST11) have been found associated with KOA through GWAS in 
European, Asian and Caucasians populations [29, 30]. Candidate gene studies have 
been responsible for identifying several susceptible loci for OA. GDF5, ASPN, FRZB 
and PTGS2 are few other genes which have been identified this way. These genes 
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continue to be the subject of functional studies and further genetic replication in 
independent populations [31–36].
Valdev et al. [37] reported an association between an amino acid variant in the 
TRPV1 gene and risk of symptomatic KOA for the first time. This amino acid has 
been implicated in pain sensitivity previously. The observation that the genotype 
implicated in lower pain sensitivity is significantly associated with a lower risk of 
painful OA. After adjustment for confounding variables (age, sex, BMI and radio-
graphic severity) the difference between symptomatic and asymptomatic OA also 
achieves statistical significance.
Knee OA subjects showed individual characteristics in their expression of PBMC 
gene. A set of 173 genes was identified to diagnose Knee OA cases. The sensitivity 
and specificity were 89% and 76% respectively [38]. Besides, they observed that 
patients with symptomatic KOA could be categorized into two distinct groups 
based on the level of inflammatory gene expression (e.g., IL-1β, IL-8, COX-2). The 
differential overexpression of these inflammatory genes in KOA subclasses was 
validated using qPCR (P < 0.0001) in 2 cohorts from NYUHJD and one cohort from 
Duke University.
Yerges Armstrong et al. [39] identified four SNPs significantly associated with 
radiographic KOA. The strongest signal (p = 0.0009) maps to 12q3, which contains 
a gene coding for SP7. Additional loci map to 7p14.1 (TXNDC3), 11q13.2 (LRP5) and 
11p14.1 (LIN7C). The allele associated with higher BMD was also associated with 
higher odds of KOA in all four loci. This meta-analysis demonstrated that several 
GWAS identified BMD SNPs are nominally associated with prevalent radiographic 
KOA and further supports the hypothesis that BMD or its determinants may be a 
risk factor contributing to OA development.
A study by Shi-Xing Luo et al. [40] on IL-16 showed a significant association 
of SNP rs4778889 with altered gene expression levels as well as two other SNPs 
(rs11556218 and rs4072111). The latter two SNPs are located in an exon region, 
and their single nucleotide change results in an amino acid substitution. This was 
the first study to investigate the association of IL16 polymorphism with KOA risk, 
and a significant effect was observed IL16 rs1155218. Polymorphism represented 
an Asn to Lys substitution in exon 6 of the gene. It was mentioned that individual 
with rs11549465 C allele was at lower risk to develop the disease than those with T 
allele. Javier Fernández-Torres et al. [41] found that the SNP rs11549465 located in 
the exon 12 within the HIF1A gene was associated with KOA in Mexican patients. 
Their results showed that the presence of the CC homozygous variant or C allele 
represents potential risk factors for development of KOA. On the contrary to this, 
they detected that the heterozygous variant of CT or T allele of the rs11549465 poly-
morphism of the HIF1A gene (in comparison with the homozygous carriers) play a 
protective role against the disease.
Rui Zhang et al. [32] demonstrated that SNP rs143383 of GDF5 is a compelling 
risk factor for both knees and hand OA and provide further support for GDF5 
in etiology of OA. A recent study by Kwo Wei Ho et al. [42] suggested that the 
COL11A2, a collagen-encoding gene, may play a role in pain sensitization after the 
development of OA. In a case-control study, Haohuan Li et al. [43] investigated 
the association between EN1 rs4144782 and susceptibility to KOA in a Chinese 
population. A significant association of SNP was observed with increased risk of 
KOA. The results reconfirmed the close connection between BMD and OA.
Indian scenario: Besides our studies, not much work has been done on the asso-
ciation of SNPs in the Indian population. Studies published from our laboratory on 
genetic polymorphism in KOA demonstrated an association of BMP5, CCL2, COL2A1, 
IL1B, SMAD3, GDF5, ESR-α, CALM1 and COMP genes with the development of 
KOA. Background of these genes is given below.
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4. Bone morphogenic protein (BMP5) gene
BMP5 is a member of the TGF-β superfamily of secreted proteins whose family 
members are involved in synovial joint development and joint tissue homeostasis 
[44]. Hahn et al. [45] reported that BMP5 was found on human chromosome 6p12.1.
BMPs were originated as protagonists of bone formation and growth. They have 
a major role in morphogenesis of a variety of vertebrate tissues and organs. They 
stimulate all proliferation and matrix synthesis for differentiation of chondrocytes. 
BMP5, in particulate, are known to regulate ovarian development [8, 46], cardiac 
development [47], and limb bud development [48] with a well-defined role in the 
differentiation of chondrocytes through the promotion of cell proliferation and 
matrix synthesis [49, 50]. Southam et al. [51] found that Polymorphisms located 
within the transcribed region of BMP5 and its proximal promoter had previ-
ously been excluded for association with OA. Nevertheless, there is increasing 
evidence; however, that polymorphisms in regulatory elements involved in gene 
transcription play an important role in conferring susceptibility to complex disease 
traits [52].
The studies carried out in multiple organisms demonstrated its role in the regu-
lation of various episode of embryonic development which includes dorsal-ventral 
and left-right axis formation, mesenchymal-epithelial interactions, and differentia-
tion of many specific tissues including lung, gut, kidney, hair, teeth, cartilage, and 
bone [7]. BMPs can trigger the entire process of cartilage and bone formation when 
implanted at ectopic sites in adult animals [53] and are usually expressed in and 
around early cartilage and bone precursors during embryonic development [54–57]. 
Moreover, mutations in different BMP genes block the formation of particular 
skeletal features, showing that BMPs are also required for the normal formation of 
skeletal tissue [58].
BMP1 is a protease which takes part in the maturation of fibrillar collagens 
whereas the other BMPs are secreted molecules of TGF-beta family [59, 60].
BMPs influence the normal development and repair of the synovial joint; 
therefore alterations in the activity of these molecules could affect the arthritic 
phenotype [61, 62]. Using genetic association analysis, we have tested BMP5 as the 
chromosome 6 OA susceptibility gene. Zuzarte-Luis et al. [63] provided evidence 
for a role of this BMP member in the development of limb autopodium through 
the activation of Smad proteins and MAPK p38. Previous studies demonstrate that 
secreted signaling molecules in the bone morphogenetic protein (BMP) family play 
a vital role in both formation and repair of skeletal structures. These molecules are 
expressed both in early skeletal precursors and in the surface perichondrium and 
periosteum layers that surround growing cartilage and bone [64].
Wilkins et al. [65] identified an SNP and a functional microsatellite associated 
with OA. It has been exhibited that various alleles of microsatellite are behind the 
modified transcriptional activity of BMP5 promoter suggestive of cis-regulation of 
BMP5, is involved in OA susceptibility.
5. Chemokine (C-C motif ) ligand 2 (CCL2) gene
Chemokines are small, secreted proteins that stimulate the directional migra-
tion of leukocytes and mediate inflammation (Baggiolini et al, 1997). These are 
a family of heparin-binding cytokines known for this chemotactic activity. Four 
subfamilies of chemokines have been identified based on the juxtaposition of 
cysteine residues in the protein’s N-terminus. These families have been named C, 
C-C, C-X-C, and C-X3-C [66].
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Sozzani et al. [67] said that the C-C and C-X-C chemokines represent two 
significant subgroups. The C-X-C chemokines include IL-8 and growth-related 
oncogene a. The C-C chemokine family comprises families of monocyte chemoat-
tractant proteins (e.g. MCP-1, MCP-2, MCP-3), macrophage inflammatory proteins 
(e.g., MIP-1a and MIP-1b), and a chemokine designated RANTES (regulated upon 
activation, normal T cell expressed and secreted). As their names suggest, these 
chemokines act predominantly on mononuclear cells (e.g., T cells, monocytes, and 
macrophages).
CCL2; previously known as monocyte chemoattractant protein-1, MCP-1 is a 
chemoattractant that belongs to the CC chemokine subfamily. Mehrabian et al. [68] 
localized the gene for monocyte chemotactic protein-1 (CCL2) to chromosome 17. 
Corrigall et al. 2001 proposed that CCL2 in the synovial membrane serves to recruit 
macrophages and perpetuate inflammation in the joints of patients with rheuma-
toid arthritis. CCL2 plays a crucial role in host defense by recruiting monocytes and 
macrophages at the site of inflammation [69].
CCL2 production is inducible in various types of cells, including synoviocytes 
[70]. In several studies, increased expression of CCL2 was observed in patients 
with inflammatory diseases, including neuropsychiatric syndromes of systemic 
lupus erythematosus, rheumatoid arthritis, OA and degenerative and inflammatory 
arthropathies, including gout [71–73].
Reports have demonstrated the involvement of chemokines in cartilage 
abnormalities in OA [74–76]. Reported studies suggests that CCL2 is involved in 
inflammatory diseases such as RA and OA, However, in previous studies, the CCL2 
gene polymorphism (22510A/G) did not show any association with Spanish and 
Korean RA [77, 78]. However, Park et al. [79] investigate that significant associa-
tion between polymorphisms of the CCL2 gene and primary knee OA patients in a 
Korean population.
6. Collagen, type II, alpha 1 (COL2A1) gene
Solomon et al. [80] suggest that the human type II collagen gene, COL2A1, has 
been assigned to chromosome 12.
Law et al. [81, 82] said a cosmid clone containing the entire human type II alpha 
one collagen gene (COL2A1) was used as a probe in the Southern analysis of DNA 
from a panel of human/hamster somatic cell hybrids containing different portions 
of human chromosome 12. Two of the hybrids exhibited a similar terminal dele-
tion q14.3----qt, but one was positive for the gene while the other was negative. 
Therefore, the gene must reside in the region q14.3.
Holderbaum et al. [83, 84] referred a single base change resulting in the substitu-
tion of Cys for Arg at position 519 of the type II collagen triple helix is a predisposing 
factor in the pathogenesis of a precocious-onset form of familial Osteoarthritis 
associated with a mild chondrodysplasia. Cartilage obtained at the time of total 
knee replacement in a patient with the Arg-Cys519 mutation was used to investigate 
the expression of Col2A1 alleles. Using PCR assisted amplification of mRNA with 
specific amplification of a region of Col2A1 message encompassing exons 31-34, 
followed by single-strand conformation polymorphism and sequence analyses, 
we have found transcription products of both mutant and normal type II collagen 
alleles. Further analysis of the sequence of these exons provides evidence that the 
Arg-Cys519 mutation arose independently in at least two of the three known affected 
families. The presence of both mutant and normal alleles of Col2A1 in cDNA derived 
from cartilage obtained from this patient suggests that Cys519-containing type II 
collagen may continue to be produced even in advanced stages of Osteoarthritis.
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On the other hand, mutations in Type II procollagen (COL2A1) can cause a 
hereditary form of the joint disorder with a broad spectrum of phenotypes ranging 
from primary OA with mild chondrodysplasia, mild spondyloepiphyseal dysplasia 
and osteonecrosis to severe generalized OA, including achondrogenesis and hypo-
chondrogenesis [85].
The COL2A1 gene appears to play a crucial role in OA pathogenesis because the 
protein encoded is the most abundant in articular cartilage. However, results of the 
studies searching for a relationship between COL2A1 and OA are controversial, due 
to that an association with specific genotypes has been reported in some studies, 
whereas others have denied this. We found no association between OA of the knee 
and COL2A1 gene polymorphism in the overall sample. Nevertheless, when the 
association was analyzed according to radiologic grade, a significant relationship 
was denoted in OA grade 4 with allele p (Pp/pp) [OR (95% CI) 4.1 (1.2¡14.6)] 
independently of gender, age, and BMI; this indicates that in Mexican Mestizo 
population, a COL2A1 gene polymorphism is associated with advanced stages of OA 
of the knee [86–89].
The study of Mu et al. [90] does not fully support that COL2A1 could be impli-
cated in primary OA of other non-Asian ethnic groups since ethnic variability in 
gene susceptibility is very well documented. The clinical features of early-onset OA, 
mild clinical phenotypes and one patient with osteonecrosis of the femoral head 
strongly suggested that COL2A1 may also be the underlying cause of OA in our 
family. Linkage analysis and direct sequencing of COL2A1, however, clearly rule out 
this possibility. Kannu et al. [91] have been described COL2A1 mutations in associa-
tion with bilateral hip disease and Osteoarthritis in the second decade of life but 
without ocular abnormalities or short stature. Xu et al. [92] investigate the relation-
ships between two COL2A1 single nucleotide polymorphisms (SNPs; T2088C and 
G4006A) and Osteoarthritis (OA) in Han Chinese women.
7. Interleukin 1 beta (IL1B) gene
Loughlin et al. [93] said that IL-1 is the primary catabolic cytokine of the OA 
joint and can stimulate the synthesis of several proteinases, which can result in 
the breakdown of cartilage extracellular matrix proteins. The 2 IL-1 genes (IL1A 
and IL1B) and the gene encoding IL-1Ra (IL1RN) are located on chromosome 2q13 
within a 430-kb genomic fragment [94]. Loughlin et al. 2002 reported that IL-1R 
antagonist (IL-1Ra) competes with IL-1 for binding to the IL-1 receptors and can 
act as an inhibitor of cartilage loss. When the catabolic and anabolic activities of the 
cytokines are balanced, cartilage integrity is maintained. If there is an imbalance 
favoring catabolism, however, cartilage destruction can proceed, resulting in OA. 
It is, therefore, reasonable to propose that a proportion of the genetic susceptibil-
ity to OA may be encoded for by variation in the activity of interleukins and that 
for chromosome 2q this susceptibility could reside within the IL-1 gene clusters. 
Stern et al. [95] reported that IL1B 5810 G > A SNP genotypes marker were not in 
Hardy-Weinberg equilibrium (p < 0.05 in both non-erosive and erosive hand OA 
subgroups). Statistically significant association with the IL1B 5810 AA genotype 
was found in the erosive hand OA subgroup (relative risk 3.8, p = 0.007). This IL1B 
5810 AA genotype association was also significant between erosive and non-erosive 
hand OA subjects (relative risk 4.01, p = 0.008). As expected, significant linkage 
disequilibrium was present between IL1B 5810 SNP and IL1A (−)889 SNP, other 
IL1B SNPs, and the nearest IL1RN SNP examined. The IL1B 5810A allele occurs 
most frequently on haplotypes with the SNP alleles IL1B 1423C, IL1B 1903 T, IL1B 
5887C, and IL1A (−)889C. Genotypes at null loci failed to show evidence suggesting 
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population stratification that might account for the spurious association. Sezgin  
et al. [95] said that some researchers had suggested an association between the IL-1 
gene cluster and the occurrence of OA.
Previously, Moos et al. [96] investigated the distribution of polymorphic alleles 
of four different genes encoding TNF-alpha, IL1RN, IL1B and IL-6 in the knee 
or hip OA patients with controls. The analysis of genotype frequencies for the 
IL1B gene, more OA patients than controls was homozygous for allele 2, although 
any significant differences for the TNF-alpha, IL1RN and IL-6 polymorphisms 
were found.
8. SMAD3 (SMAD family member 3) gene
Smad3 was found on human chromosome 15q22.33.The classic TGF-β mediated 
signaling pathway involves Smad activation. Smads are a family of intracellular 
proteins that comprise three classes of signaling molecules: - receptor-associated 
Smads (2 and 3 for TGF- β, 1, 5, and 8 for BMP signaling), the co-factor Smad4, and 
the inhibitory Smads (6and7) [97]. The receptor-activated SMADs include SMADs 
1, 2, 3, 5, and 8. SMADs 2 and 3 respond to TGF- β and activins [97, 98], whereas 
SMAD1, 5, and 8 function in BMP signaling pathways [99–101]. The receptor-asso-
ciated Smads bind to the type I receptor, and on ligand binding and activation, are 
phosphorylated and released into the cytoplasm. The activated receptor-associated 
Smads form a trimeric heterodimer with the co-factor Smad4, translocate to the 
nucleus, and influence gene transcription [102].
Yao et al. [103] reported that Smad3 gene mutation is a possible predisposing 
factor for human OA and found gene mutation in OA, providing insight into the 
function of SMAD3 mediated TGF-b signals in the development of OA and also 
suggested that Smad3 gene mutation may be a risk factor for genetic suscepti-
bilities to OA.
Ferguson et al. [104] has established that the TGF- β Smads inhibit chondrocyte 
maturation, whereas the BMP-related Smads accelerate maturation. Many studies 
have shown that transforming growth factor- β (TGF- β) signals function as crucial 
regulators in bone formation, remodeling and maintenance. [105]. Micheal et al. 
[106] have shown that loss of Smad3 results in impaired immune responses, acceler-
ated wound healing decreased bone density, OA and access to colon cancer.
Yang et al. [107] showed that Smad3-mediated TGF- β signals are essential for 
maintaining articular cartilage in the quiescent state by repressing chondrocyte dif-
ferentiation and controlling matrix molecule synthesis. Consequently, impairment 
of TGF-b signals due to Smad3 disruption results in phenotypes resembling human 
Osteoarthritis.
Wu et al. [108] suggested that Loss of Smad3 appears to enhance bone morpho-
genetic protein signaling in the articular chondrocytes, leading to hypertrophy and 
OA-like changes. The observation further supports the crucial role of Smad3 that 
Smurf2 overexpression leads to dephosphorylation of Smad3 and is associated with 
a spontaneous OA phenotype in transgenic mice.
Also, Cherlet et al. [109] reported that Smad3 levels are lower in women than 
in men, which is consistent with other data showing that estrogens inhibit SMAD3 
transcriptional activity Nevertheless, Valdes et al. found that the genetic association 
of the SMAD3 intronic SNP with OA was significant in both men and women and 
that effect sizes were remarkably similar between sexes, confirming the robustness 
of the result. Valdes et al. [109] reported that four SNPs (rs266335, rs12901499, 
rs6494629, and rs2289263) were found to be nominally significantly associated with 
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knee OA (P < 0.05), but only 1 of them, rs12901499, was nominally associated also 
with hip OA (P < 0.021) and also observed that the major allele G was found at a 
higher frequency among OA patients than among controls [109–112].
9. Growth differentiation factor-5 (GDF-5)
Hotten et al. [9] determined that the GDF5 gene contains two exons. Miyamoto 
et al. [113] reported that the gene encoding growth differentiation factor-5 
(GDF-5) is associated with Osteoarthritis in Asian populations. An SNP in the 
5′ untranslated region (UTR) of GDF-5 showed significant association with hip 
osteoarthritis in 2 independent Japanese populations. This association was repli-
cated for knee osteoarthritis in Japanese and Han Chinese populations. This SNP, 
located in the GDF-5 core promoter, exert allelic differences on transcriptional 
activity in chondrogenic cells, with the susceptibility allele showing reduced 
activity. The findings implicated GDF-5 as a susceptibility gene for Osteoarthritis 
and suggested that decreased GDF-5 expression is involved in the pathogenesis 
of Osteoarthritis. [2] also isolated and characterized human GDF5, which they 
designated CDMP1, as well as human GDF6 (CDMP2). GDF6 is predominantly 
expressed at sites of skeletal morphogenesis. Al-Yahyaee et al. [114–117] identified 
two mutations in the GDF5 gene: a silent 1137A-G transition encoding lysine and 
a 1-bp deletion, 1144delG, predicting a frame shift resulting in loss of the biologi-
cally active C terminus of the protein. Thomas et al. [118] found that heterozy-
gotes for the C400Y mutation had phenotypes resembling brachydactyly types A1, 
A4, or C.
10. Estrogen receptor alpha (ESR- α) gene
The estrogen receptor (ESR-α) is a ligand-activated transcription factor 
composed of several domains essential for hormone binding, DNA binding, and 
activation of transcription. Alternative splicing results in several ESR-α mRNA 
transcripts, which differ primarily in their 5′ untranslated regions. The translated 
receptors show less variability [4, 119]. Ponglikitmongkol et al. [120, 121] showed 
that the human ESR-α gene is more than 140 kb long. It contains eight exons, and 
the position of its introns has been highly conserved, being, for example, remark-
ably similar to those of one of the chicken thyroid hormone receptor genes. Sputnik 
et al. [122] reported that ESRα isoform is a ligand-activated transcription factor 
composed of several essential domains for hormone binding and activation of 
transcription. ESRα is an essential mediator in the signal transduction pathway. Jin 
et al. [123] reported that Estrogen receptors (ESR-α) are known to play an essential 
role in the pathophysiology of Osteoarthritis. To investigate ESRα gene polymor-
phisms for its association with primary knee osteoarthritis, they conducted a case-
control association study in patients with primary knee osteoarthritis and healthy 
individual in the Korean population. Jin et al. (2004) investigated the association 
between haplotypes of three polymorphism in PVU II in intron 1(IVS1-397 T/C), 
Xba I in intron 1(IVS1-351A/G) and Big I in exon 8 (exon8 229G/A) of ESR-α gene 
and primary knee OA in the Korean population, first two SNP in intron one also 
investigated by Bergink et al. [124] in Rotterdam population. Ushiyama et al. [125] 
found on ESR-α gene association between a genotype of PVU II and Xba I polymor-
phisms in Intron 1 and generalized Osteoarthritis with a severe radiographic change 
in the Japanese population.
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11. Calmodulin 1 (CALM1) gene
Rhyner et al. [126] found that the CALM1 gene contains six exons spread over 
about 10 kb of genomic DNA. The exon-intron structure was identical to that of 
CALM3. A cluster of transcription-start sites was identified 200 bp upstream of the 
ATG translation-start codon, and several putative regulatory elements were found 
in the 5′ flanking region, as well as in intron 1. A short CAG trinucleotide repeat 
region was identified in the 5-prime untranslated region of the gene. Motoani et al. 
[127] identified susceptibility genes for Osteoarthritis in a large-scale case-control 
association study using gene-based single-nucleotide polymorphism (SNPs) in a 
Japanese population. In two independent case-control populations, they found a 
significant association (p = 9.8 x10−7) between hip osteoarthritis and an SNP (IVS 
3–293 C>T) located in intron 3 of the calmodulin (Cam) 1 gene (CALM-1). CALM 1 
was expressed in cultured chondrocytes, and articular cartilage and its expression 
were increased in Osteoarthritis. Subsequent linkage – disequilibrium mapping 
identified five SNPs showing significant equivalent to IVS 3–293 C>T. One of these 
(−16 C>T) is located in the core promoter region of CALM 1. Functional analysis 
indicated that the susceptibility – 16 T allele decreases CALM 1 transcription 
in-vitro and in-vivo. Inhibition of CAM in chondrogenic cells reduced the expres-
sion of the major cartilage matrix genes col 2a1 and Agc 1. These results suggested 
that the transcriptional level of CALM-1 was associated with susceptibility for 
hip osteoarthritis through modulation of chondrogenic activity. Their findings 
revealed that the CALM-1 mediated signaling pathway is chondrocytes as a novel 
potential target for the treatment of Osteoarthritis. Loughlin et al. [128] studied 
in a Caucasian population using a cohort of 1672 individuals and concluded that 
CALM-1 core promoter polymorphism is not a risk factor for Osteoarthritis.
12. Cartilage oligomeric matrix protein (COMP) gene
Briggs et al. [129] demonstrated that the COMP gene contains 19 exons. Exons 
4-19, which encode the EGF-like (type II) repeats, calmodulin-like (type III) repeats 
(CLRs), and the C-terminal domain, correspond in sequence and intron location to 
the thrombospondin genes, whereas exons 1-3 are unique to COMP. Mabuchi  
et al. [130] reported that hereditary osteochondral dysplasia produces severe early-
onset OA Among them are Pseudochondroplasia (PSACH) & multiple epiphyseal 
dysplasias (MED) both of which are caused by a mutation in the COMP gene. 
Therefore COMP may be a susceptibility gene for OA. For these reasons, Mabuchi 
et al. [131] hypothesized that Osteoarthritis is a common disorder may be at the 
mild end of the phenotypic gradation produced by COMP mutations. They ascer-
tained the sequences of the exons and exon-intron boundaries and identified 16 
polymorphisms in the COMP gene. Using five polymorphisms spanning the entire 
COMP gene (−1417 C/G in promoter region with P = 0.29, c.279C/A in exon 4 with 
P = 0.19, IVS5 + 76 T/C with P = 0.74, IVS16-45C/T with P = 0.19 and IVS18-40 T/C 
with P = 0.93), Mabuchi et al. [132], examined the association of this gene in Japanese 
patients with Osteoarthritis of the knee and hip joints. Genotype and allele frequen-
cies of the polymorphisms were significantly different between osteoarthritis and 
control groups, and with the help of this study, they hypothesize that comp gene is 
a candidature gene for OA Song et al. [133] identified mutations in the COMP gene 
in 9 of 9 Korean patients with PSACH and 3 of 5 Korean patients with MED. Three 
of the eight mutations identified were novel. Deere et al. identified 12 mutations in 
the COMP gene, including ten novel mutations in 12 patients with PSACH. The site 
of the mutations emphasized the importance of the calcium-binding domains and 
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the globular domain to the function of COMP. Kennedy et al. reported three SNPs in 
COMP, first in exon-11, nucleotide change A>G at c1156 with allelic frequency 0.03, 
second in exon −16, nucleotide change G>A at c17.55 with allelic frequency 0.05, and 
last third one is in 3’UTR, Nucleotide change A>G at c2289 with allelic frequency 
0.005 which are associated with OA [133].
CALM1 gene showed a significant association of SNP with the disease. CALM1 
gene intronic SNP (rs3213718) was present in our population, and its occurrence 
was significantly affecting the disease.
A case-control study of 600 subjects showed a significant association of 
the+104 T/C GDF5 polymorphism with KOA and with individual clinical symptoms 
of the disease. A study done by Srivastava et al. reported that genetic polymorphisms 
affecting KOA vary between genders and indicate a role for BMP5, COL2A1, CCL2, 
and IL1B in North Indian Population. Another case-control study of 499 KOA cases 
and 458 controls exhibited an association between rs1470527, rs9382564 polymor-
phisms of BMP5 gene with KOA. This association was validated by haplotype analysis. 
Further, the association between KOA and rs1470527 polymorphism was more 
robust in both the genders and age groups. However, association with rs9382564 was 
stronger only in female patients and either gender aged >55 years. Moreover, our data 
showed a significant association of both SNPs with VAS and WOMAC clinical scores.
Furthermore, a genetic study conducted in our laboratory on SNPs rs921126 
(BMP5) and rs12901499 (SMAD3) showed a significant association between these 
SNPs and risk of KOA. It was found that the risk increased with age (>55) in both 
the genders. We also conducted a pilot study on VDR gene polymorphism and 
its association with KOA. It was found that Taq1 polymorphism influenced the 
clinico-radiological response to vitamin D supplementation in KOA subjects with 
insufficient 25(OH) vitamin D levels. Validation of the results is in process on large 
population with insufficient 25(OH) vitamin D levels.
An extensive literature search, we could find only one more study conducted in 
Indian population other than ours, by Subramanyam et al. They studied the associa-
tion of rs73297147 and rs73771337 polymorphisms in COL2A1 and CRTL1 genes with 
primary KOA in South Indian population, and a significant association was observed.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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